These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 8396511

  • 1. 17-Hydroxyprogesterone response to buserelin testing in the polycystic ovary syndrome.
    Sahin Y, Keleştimur F.
    Clin Endocrinol (Oxf); 1993 Aug; 39(2):151-5. PubMed ID: 8396511
    [Abstract] [Full Text] [Related]

  • 2. 17-Hydroxyprogesterone responses to gonadotrophin-releasing hormone agonist buserelin and adrenocorticotrophin in polycystic ovary syndrome: investigation of adrenal and ovarian cytochrome P450c17alpha dysregulation.
    Sahin Y, Keleştimur F.
    Hum Reprod; 1997 May; 12(5):910-3. PubMed ID: 9194638
    [Abstract] [Full Text] [Related]

  • 3. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
    White D, Leigh A, Wilson C, Donaldson A, Franks S.
    Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
    [Abstract] [Full Text] [Related]

  • 4. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R, Patton L, Pocognoli P, Cognigni GE, Gambineri A.
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The effect of sequential administration of octreotide alone and octreotide/growth hormone simultaneously on buserelin stimulated ovarian steroid secretion in women with polycystic ovary syndrome.
    Piaditis GP, Hatziioanidis AH, Trovas GP, Misichronis GS, Kounadi TG, Devetzaki OA, Andronis CK, Rangou DB, Chlouverakis CS.
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):595-604. PubMed ID: 8977757
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
    Unlühizarci K, Keleştimur F, Bayram F, Sahin Y, Tutuş A.
    Clin Endocrinol (Oxf); 1999 Aug; 51(2):231-6. PubMed ID: 10468995
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ovarian suppression in polycystic ovarian disease during 6 month administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
    Faure N, Lemay A.
    Clin Endocrinol (Oxf); 1987 Dec; 27(6):703-13. PubMed ID: 3138052
    [Abstract] [Full Text] [Related]

  • 15. Value of buserelin testing in the evaluation of hirsute women.
    Ambrosi B, Re T, Passini E, Bochicchio D, Ferrario R.
    J Endocrinol Invest; 1996 Apr; 19(4):204-9. PubMed ID: 8862498
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.